Published in Cancer Chemother Pharmacol on November 07, 2003
Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis (2013) 3.07
The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr (2007) 2.07
2-deoxy-D-glucose enhances anesthetic effects in mice. Anesth Analg (2015) 1.99
Synthesis enables identification of the cellular target of leucascandrolide A and neopeltolide. Nat Chem Biol (2008) 1.83
Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer (2013) 1.57
Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger breast cancer cell death. Cancer Res (2012) 1.49
Akt and c-Myc differentially activate cellular metabolic programs and prime cells to bioenergetic inhibition. J Biol Chem (2009) 1.48
Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. Prostate (2010) 1.45
Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth. Cancer Cell Int (2016) 1.42
Silencing of elongation factor-2 kinase potentiates the effect of 2-deoxy-D-glucose against human glioma cells through blunting of autophagy. Cancer Res (2009) 1.42
2-Deoxy-D-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion. Cancer Chemother Pharmacol (2010) 1.35
The oncoprotein H-RasV12 increases mitochondrial metabolism. Mol Cancer (2007) 1.33
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death. Anticancer Res (2009) 1.19
Anticancer agents that counteract tumor glycolysis. ChemMedChem (2012) 1.17
Non-thermal plasma with 2-deoxy-D-glucose synergistically induces cell death by targeting glycolysis in blood cancer cells. Sci Rep (2015) 1.13
Enhanced radiosensitivity and chemosensitivity of breast cancer cells by 2-deoxy-d-glucose in combination therapy. J Breast Cancer (2012) 1.11
Metabolic signature identifies novel targets for drug resistance in multiple myeloma. Cancer Res (2015) 1.08
Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells. Front Oncol (2015) 1.05
Metabolism addiction in pancreatic cancer. Cell Death Dis (2014) 1.02
Emerging metabolic targets in cancer therapy. Front Biosci (Landmark Ed) (2011) 1.02
Molecular Connections between Cancer Cell Metabolism and the Tumor Microenvironment. Int J Mol Sci (2015) 0.99
From delocalized lipophilic cations to hypoxia: blocking tumor cell mitochondrial function leads to therapeutic gain with glycolytic inhibitors. Mol Nutr Food Res (2009) 0.99
p53 Protects lung cancer cells against metabolic stress. Int J Oncol (2010) 0.96
Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biol Ther (2012) 0.96
Metabolic alterations in cancer cells and therapeutic implications. Chin J Cancer (2011) 0.96
Targeting metabolism to induce cell death in cancer cells and cancer stem cells. Int J Cell Biol (2013) 0.94
Cell metabolism: an essential link between cell growth and apoptosis. Biochim Biophys Acta (2010) 0.92
Caloric restriction mimetic 2-deoxyglucose antagonizes doxorubicin-induced cardiomyocyte death by multiple mechanisms. J Biol Chem (2011) 0.92
FTS and 2-DG induce pancreatic cancer cell death and tumor shrinkage in mice. Cell Death Dis (2012) 0.92
Autophagy in pancreatic cancer. Int J Cell Biol (2012) 0.90
BIRC5/Survivin as a target for glycolysis inhibition in high-stage neuroblastoma. Oncogene (2015) 0.88
The genome-wide expression profile of 1,2,3,4,6-penta-O-galloyl-β-D-glucose-treated MDA-MB-231 breast cancer cells: molecular target on cancer metabolism. Mol Cells (2011) 0.87
The Warburg effect revisited--lesson from the Sertoli cell. Med Res Rev (2014) 0.86
p53 is an important factor for the radiosensitization effect of 2-deoxy-D-glucose. Int J Oncol (2009) 0.86
The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma. Invest New Drugs (2010) 0.86
Cancer cell bioenergetics and pH regulation influence breast cancer cell resistance to paclitaxel and doxorubicin. J Bioenerg Biomembr (2013) 0.85
Glucose deprivation in tuberous sclerosis complex-related tumors. Cell Biosci (2011) 0.85
Focal, periocular delivery of 2-deoxy-D-glucose as adjuvant to chemotherapy for treatment of advanced retinoblastoma. Invest Ophthalmol Vis Sci (2010) 0.84
Nitric oxide synthase inhibition enhances the antitumor effect of radiation in the treatment of squamous carcinoma xenografts. PLoS One (2011) 0.83
Advanced retinoblastoma treatment: targeting hypoxia by inhibition of the mammalian target of rapamycin (mTOR) in LH(BETA)T(AG) retinal tumors. Clin Ophthalmol (2011) 0.80
Inhibition of transketolase by oxythiamine altered dynamics of protein signals in pancreatic cancer cells. Exp Hematol Oncol (2013) 0.80
Regression of Dalton's lymphoma in vivo via decline in lactate dehydrogenase and induction of apoptosis by a ruthenium(II)-complex containing 4-carboxy N-ethylbenzamide as ligand. Invest New Drugs (2008) 0.80
Deoxyglucose prevents neurodegeneration in culture by eliminating microglia. J Neuroinflammation (2014) 0.79
Inhibition of Aerobic Glycolysis Attenuates Disease Progression in Polycystic Kidney Disease. PLoS One (2016) 0.78
Oleanolic Acid Inhibits High Salt-Induced Exaggeration of Warburg-like Metabolism in Breast Cancer Cells. Cell Biochem Biophys (2016) 0.78
The combination of tephrosin with 2-deoxy-D-glucose enhances the cytotoxicity via accelerating ATP depletion and blunting autophagy in human cancer cells. Cancer Biol Ther (2011) 0.78
Investigational cancer drugs targeting cell metabolism in clinical development. Expert Opin Investig Drugs (2014) 0.78
Glucose metabolism in gastric cancer: The cutting-edge. World J Gastroenterol (2016) 0.78
2-Deoxy-d-Glucose Can Complement Doxorubicin and Sorafenib to Suppress the Growth of Papillary Thyroid Carcinoma Cells. PLoS One (2015) 0.78
Retinoblastoma treatment: utilization of the glycolytic inhibitor, 2-deoxy-2-fluoro-D-glucose (2-FG), to target the chemoresistant hypoxic regions in LH(BETA)T(AG) retinal tumors. Invest Ophthalmol Vis Sci (2012) 0.78
Lactate dehydrogenase-A inhibition induces human glioblastoma multiforme stem cell differentiation and death. Sci Rep (2015) 0.77
The bifunctional autophagic flux by 2-deoxyglucose to control survival or growth of prostate cancer cells. BMC Cancer (2015) 0.77
Dynamic scenario of metabolic pathway adaptation in tumors and therapeutic approach. Oncoscience (2015) 0.77
Metabolic targeting of oncogene MYC by selective activation of the proton-coupled monocarboxylate family of transporters. Oncogene (2015) 0.77
Adipose tissue dysfunction and its effects on tumor metabolism. Horm Mol Biol Clin Investig (2015) 0.77
Increased sensitivity to glucose starvation correlates with downregulation of glycogen phosphorylase isoform PYGB in tumor cell lines resistant to 2-deoxy-D-glucose. Cancer Chemother Pharmacol (2013) 0.76
The isatin-Schiff base copper(II) complex Cu(isaepy)2 acts as delocalized lipophilic cation, yields widespread mitochondrial oxidative damage and induces AMP-activated protein kinase-dependent apoptosis. Carcinogenesis (2009) 0.76
Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/ mTOR signaling. Oncotarget (2016) 0.76
2-Deoxy-2-fluoro-d-glucose metabolism in Arabidopsis thaliana. Front Plant Sci (2015) 0.76
Targeting glucose metabolism in cancer: new class of agents for loco-regional and systemic therapy of liver cancer and beyond? Hepat Oncol (2016) 0.76
Cellular effects of fluorodeoxyglucose: Global changes in the lipidome and alteration in intracellular transport. Oncotarget (2016) 0.75
A validated bioanalytical HPLC method for pharmacokinetic evaluation of 2-deoxyglucose in human plasma. Biomed Chromatogr (2011) 0.75
Retinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomics expression in LH(BETA)T(AG) retinal tumors. Clin Ophthalmol (2012) 0.75
Mitochondrial-Targeted Decyl-Triphenylphosphonium Enhances 2-Deoxy-D-Glucose Mediated Oxidative Stress and Clonogenic Killing of Multiple Myeloma Cells. PLoS One (2016) 0.75
Sorafenib and 2-Deoxyglucose Synergistically Inhibit Proliferation of both Sorafenib Sensitive and Resistant HCC Cells by Inhibiting ATP Production. Gene Expr (2016) 0.75
Prospects on strategies for therapeutically targeting oncogenic regulatory factors by small-molecule agents. J Cell Biochem (2014) 0.75
Targeting energy metabolism of cancer cells: Combined administration of NCL-240 and 2-DG. Int J Pharm (2017) 0.75
Glycolysis and the Hexosamine Biosynthetic Pathway as Novel Targets for Upper and Lower Airway Inflammation. Allergy Asthma Immunol Res (2018) 0.75
2-Deoxy-d-Glucose Treatment Decreases Anti-inflammatory M2 Macrophage Polarization in Mice with Tumor and Allergic Airway Inflammation. Front Immunol (2017) 0.75
2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res (2004) 2.88
Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist. Proc Natl Acad Sci U S A (2013) 2.19
Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Mol Cancer Ther (2007) 1.54
A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol (2012) 1.41
2-Deoxy-D-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion. Cancer Chemother Pharmacol (2010) 1.35
Differential toxic mechanisms of 2-deoxy-D-glucose versus 2-fluorodeoxy-D-glucose in hypoxic and normoxic tumor cells. Antioxid Redox Signal (2007) 1.26
Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose. Mol Cancer Ther (2007) 1.22
Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition. Int J Oncol (2009) 1.16
Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C). Biochem Pharmacol (2002) 1.15
Targeting hypoxia, a novel treatment for advanced retinoblastoma. Invest Ophthalmol Vis Sci (2008) 1.12
Antiangiogenic activity of 2-deoxy-D-glucose. PLoS One (2010) 1.08
Differential sensitivity to 2-deoxy-D-glucose between two pancreatic cell lines correlates with GLUT-1 expression. Pancreas (2005) 1.08
Apoptosis-based drug screening and detection of selective toxicity to cancer cells. Anticancer Drugs (2003) 1.06
Cellular volume and marker expression in human peripheral blood apheresis stem cells. Cytometry A (2008) 1.06
Efficacy of 2-halogen substituted D-glucose analogs in blocking glycolysis and killing "hypoxic tumor cells". Cancer Chemother Pharmacol (2006) 1.00
From delocalized lipophilic cations to hypoxia: blocking tumor cell mitochondrial function leads to therapeutic gain with glycolytic inhibitors. Mol Nutr Food Res (2009) 0.99
GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells. Cell Cycle (2009) 0.98
Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-D-glucose under hypoxia in lung cancer cell lines. Mol Cancer Ther (2008) 0.96
Increased hypoxia following vessel targeting in a murine model of retinoblastoma. Invest Ophthalmol Vis Sci (2009) 0.95
Inhibition of Akt potentiates 2-DG-induced apoptosis via downregulation of UPR in acute lymphoblastic leukemia. Mol Cancer Res (2012) 0.95
Multidrug resistance correlates with overexpression of Muc4 but inversely with P-glycoprotein and multidrug resistance related protein in transfected human melanoma cells. Biochem Pharmacol (2003) 0.95
Endoplasmic reticulum stress induced by 2-deoxyglucose but not glucose starvation activates AMPK through CaMKKβ leading to autophagy. Biochem Pharmacol (2013) 0.94
The wonders of 2-deoxy-D-glucose. IUBMB Life (2014) 0.94
GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer. Cell Cycle (2012) 0.90
Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers. Cell Cycle (2012) 0.90
Click-iT assay with improved DNA distribution histograms. Cytometry A (2009) 0.90
Activation of the unfolded protein response by 2-deoxy-D-glucose inhibits Kaposi's sarcoma-associated herpesvirus replication and gene expression. Antimicrob Agents Chemother (2012) 0.86
Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function. Cell Cycle (2014) 0.85
The relationship of thioredoxin-1 and cisplatin resistance: its impact on ROS and oxidative metabolism in lung cancer cells. Mol Cancer Ther (2012) 0.85
Focal, periocular delivery of 2-deoxy-D-glucose as adjuvant to chemotherapy for treatment of advanced retinoblastoma. Invest Ophthalmol Vis Sci (2010) 0.84
Microplate screening for apoptosis with antibody to single-stranded DNA distinguishes anticancer drugs from toxic chemicals. J Biomol Screen (2003) 0.83
Models and discovery strategies for new therapies of retinoblastoma. Expert Opin Drug Discov (2013) 0.83
Influence of number of CAG repeats on local control in the RTOG 86-10 protocol. Am J Clin Oncol (2006) 0.83
Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells. Cancer Lett (2010) 0.82
Conversion of 2-deoxyglucose-induced growth inhibition to cell death in normoxic tumor cells. Cancer Chemother Pharmacol (2013) 0.81
High endoplasmic reticulum activity renders multiple myeloma cells hypersensitive to mitochondrial inhibitors. Cancer Chemother Pharmacol (2009) 0.81
Hormone receptor-related gene polymorphisms and prostate cancer risk in North Indian population. Mol Cell Biochem (2008) 0.80
Apoptosis enzyme-linked immunosorbent assay distinguishes anticancer drugs from toxic chemicals and predicts drug synergism. Chem Biol Interact (2003) 0.80
Targeting cisplatin-resistant human tumor cells with metabolic inhibitors. Cancer Chemother Pharmacol (2013) 0.79
Synergistic cytotoxicity of pyrazoloacridine with doxorubicin, etoposide, and topotecan in drug-resistant tumor cells. Clin Cancer Res (2004) 0.79
Electronic volume, aldehyde dehydrogenase, and stem cell marker expression in cells from human peripheral blood apheresis samples. Cytometry B Clin Cytom (2010) 0.78
Application of anti-ssDNA monoclonal antibody to study exogenous and apoptosis-associated DNA damage. Cytometry A (2008) 0.77
Are increased tumor aneuploidy and heightened cell proliferation along with heterogeneity associated with patient outcome for carcinomas of the uterine cervix? A combined analysis of subjects treated in RTOG 9001 and a single-institution trial. Int J Radiat Oncol Biol Phys (2007) 0.77
The minimal instrumentation requirements for Hoechst side population analysis: stem cell analysis on low-cost flow cytometry platforms. Stem Cells (2006) 0.76
Increased sensitivity to glucose starvation correlates with downregulation of glycogen phosphorylase isoform PYGB in tumor cell lines resistant to 2-deoxy-D-glucose. Cancer Chemother Pharmacol (2013) 0.76
Retinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomics expression in LH(BETA)T(AG) retinal tumors. Clin Ophthalmol (2012) 0.75
Chameleon dyes which change their color on excitation. Cytometry A (2013) 0.75
Androgen & vitamin D nuclear receptor expression in archival breast tumour samples. Indian J Med Res (2006) 0.75
High resolution flow cytometric analysis of electronic nuclear volume and DNA content in normal and abnormal human tissue. Methods Cell Sci (2002) 0.75
Electronic volume of CD34 positive cells from peripheral blood apheresis samples. Cytometry B Clin Cytom (2008) 0.75
Androgen receptor expression in archival human breast tumors. Methods Cell Sci (2002) 0.75
Androgen receptor expression and DNA content of paraffin-embedded archival human prostate tumors. Cytometry (2002) 0.75